Department of Medicine, University of Calgary, Calgary, AB, Canada.
Pulmonology Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9.
Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
特发性肺纤维化（IPF）是一种复杂病因引起的进行性实质肺疾病。胃食管反流（GER）和微吸入被认为是 IPF 发生和进展的危险因素，但强有力的明确数据很少。最近的一项国际指南有条件地建议对 IPF 患者使用抗酸剂治疗（质子泵抑制剂或 H2 受体拮抗剂），而无需存在食管反流或症状。在本立场文件中，我们总结了有关 GER 与 IPF 之间关联的文献，并确定了可能阐明这一问题的未来研究重点。我们阐明了指南建议达成的过程，并旨在为照顾 IPF 患者的提供者提供建议背景。
